tomivosertib + pembrolizumab + pemetrexed

Tomivosertib + pembrolizumab + pemetrexed is an investigational combination therapy for non-small cell lung cancer (NSCLC), typically targeting patients with PD-L1 positive or nonsquamous NSCLC. **Tomivosertib** is a small molecule inhibitor of MNK1/2 that suppresses phosphorylation of eIF4E, modulating mRNA translation and potentially reducing tumor proliferation and immune suppression. **Pembrolizumab** is a monoclonal antibody targeting PD-1, functioning as an immune checkpoint inhibitor to restore immune anti-tumor activity. **Pemetrexed** is an antimetabolite (antifolate) that inhibits enzymes involved in purine and pyrimidine synthesis, causing inhibition of DNA replication in tumor cells. This triple combination aimed to improve first-line or post-progressive outcomes in NSCLC by integrating immunotherapy, targeted therapy, and chemotherapy, but clinical development in frontline NSCLC was terminated in 2024 after modest trial activity[1][5][7]. There is no unique brand name for this combination; it is referenced by its constituent drugs.

Other names

tomivosertib and pembrolizumab and pemetrexedtomivosertib + pembrolizumab + pemetrexed